肝动脉化疗栓塞免疫综合治疗肝癌的疗效观察

Transcatheter Hepatic Arterial Chemoembolization and Imunotherapy for Teatment of the Md-advanced Hepatic Carcinoma

目的观察中晚期原发性肝癌在经导管肝动脉化疗栓塞术(TACE)基础上进行免疫综合治疗的效果。方法120例中晚期肝癌患者,选择60例接受TACE介入治疗(A组),60例以TACE介入治疗为主辅助免疫综合治疗(B组),评估和随访两组患者治疗前后的疗效。结果经过治疗79.2%(95/120)临床表现缓解;88.3%(55/120)肿块大小缩小;78.2%(79/101)AFP明显下降;生存期明显延长,A组1,2,3年生存率分别为55%,18.3%,8.3%B组分别为88.3%,51.6%,36.7%。两组比较有显著性差异(P<0.05)。结论TACE免疫综合治疗是中晚期肝癌的有效手段,且为肝癌手术前治疗行之有效的方法之一,可延长患者的寿命,提高生活质量。

Objective:To observe the clinical efficiency of the tr eatment for the mid-advanced haptic carcinoma with transcatheter hepatic ar terial chemoembolization(TACE)and immunotherapy.Methods:120 patients with haptoc arcinoma were divided randomly into two groups:group A (treated by TACE)and grou p B(treated by TACE plus immunotherapy).Results:The improvement rate of symptoms and signs,decrease of alpha-fetoprotein(AFP)after treatment in both groups wer e all better.The surrival time was also prolonged in them.The 1,2,and 3 year sur rival rates were 88.3%,51.6%,and 36.7% in group A;while were 55%,16.3%,and 8.3% in group B with a significant difference(P<0.05)between the two groups.Concl usion:Treatment of mid-advanced haptic carcinoma with TACE and immunotherapy can inprove the response rate and survival time.